Soricimed gains clearance for Phase I trial of SOR-C13
The targeted peptide inhibits the non-voltage gated calcium channel found in epithelial cancers such as ovarian, breast, prostate and others. SOR-C13 has shown to induce apoptosis, inhibit cell
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.
The collaborative forum is intended to facilitate the translation of scientific research findings into clinical trials and, eventually, clinical practice. Immuno-oncology focuses on the potential of body’s own
The pre-configured version of Oracle Health Sciences Empirica Topics uses BioPharm’s methodology to facilitate the formal prioritization and evaluation of signals identified within a company. BioPharm Systems safety